OTCMKTS:CRXM Gene Biotherapeutics (CRXM) Stock Price, News & Analysis → The Hidden Tax Advantages of America’s #1 Inheritance Stock (From Stansberry Research) (Ad) Free CRXM Stock Alerts Add Compare Share Share Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Gene Biotherapeutics alerts: Email Address Ad Stansberry ResearchThe Hidden Tax Advantages of America’s #1 Inheritance StockWall Street Millionaire: BUY "America's #1 Legacy Stock" The man CNBC called "The Prophet" bought AAPL at $0.35, AMZN under $2.50, and NVDA before it soared 1,200%. Recently, he sat down for an exclusive interview, revealing EXACTLY where to put your money this year. An investment vehicle he's so confident in, he says he'd put 50% of his kids' inheritance into this stock.You can get the name and ticker symbol, absolutely free, right here. About Gene Biotherapeutics Stock (OTCMKTS:CRXM)Gene Biotherapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of angiogenic gene therapy biotherapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product candidate is Generx, an angiogenic gene therapy product candidate in Phase 3 clinical trials for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It is also developing Generx for ischemia-related cardiovascular and cerebral therapeutic indications. Gene Biotherapeutics, Inc. has an agreement with Fujifilm Diosynth Biotechnologies for the manufacture of Generx angiogenic gene therapy product for Phase 3 clinical evaluation. The company was formerly known as Taxus Cardium Pharmaceuticals Group, Inc. and changed its name to Gene Biotherapeutics, Inc. in January 2018. Gene Biotherapeutics, Inc. was incorporated in 2003 and is headquartered in San Diego, California.Read More Ad Stansberry ResearchThe Hidden Tax Advantages of America’s #1 Inheritance StockWall Street Millionaire: BUY "America's #1 Legacy Stock" The man CNBC called "The Prophet" bought AAPL at $0.35, AMZN under $2.50, and NVDA before it soared 1,200%. Recently, he sat down for an exclusive interview, revealing EXACTLY where to put your money this year. An investment vehicle he's so confident in, he says he'd put 50% of his kids' inheritance into this stock.You can get the name and ticker symbol, absolutely free, right here. CRXM Stock News HeadlinesMay 29, 2024 | finanznachrichten.deOri Biotech Ltd: Ori Biotech Unveils IRO Platform at Annual International Society for Cell & Gene Therapy ConferenceMay 29, 2024 | finance.yahoo.comCincinnati Children's to expand clinical trials with launch of Applied Gene and Cell Therapy CenterMay 29, 2024 | msn.comBroncos greatest players of all-time: #48, halfback Gene MingoMay 28, 2024 | msn.comTony Stewart, Gene Haas release statement after announcing Stewart-Haas Racing closureMay 28, 2024 | yahoo.comPTL meets the 2024 Gene Kelly and Mancini award winnersMay 27, 2024 | msn.comTRAFFIC: Part of Gene Snyder Freeway shutting down to assist LG&E with restoring powerMay 27, 2024 | msn.comGene Snyder blocked in both directions between Dixie Highway, Stonestreet RoadMay 27, 2024 | msn.com2024 Gene Kelly Awards winners announcedMay 27, 2024 | uk.finance.yahoo.comGlobal Gene Editing Tools Market Report 2024: A $3.83 Billion Market by 2034, with a CAGR of 18.84% During 2024-2034May 26, 2024 | msn.comNorth Gene Autry Trail in Palm Springs reopens; Indian Canyon Drive remains closedMay 26, 2024 | msn.com2024 Gene Kelly Awards announcedMay 23, 2024 | msn.comFour takeaways from UCLA Chancellor Gene Block's testimony on campus antisemitism, protestsMay 23, 2024 | yahoo.comGene Alexzander Scott found guilty for murdering grandfather, great-grandmother in Chester County, sentencedMay 23, 2024 | msn.com‘It Helped Me Embody Someone Else’: How ‘Cyberpunk 2077’ Helped Gene Park Battle CancerMay 23, 2024 | msn.comUCLA Chancellor Gene Block to tell Congress 'we should have been prepared to immediately remove the encampment'May 23, 2024 | msn.comUCLA Chancellor Gene Block to face Congress over campus protestsMay 22, 2024 | omaha.comGene Christensen in cockpit_editedMay 22, 2024 | msn.comUCLA Chancellor Gene Block heads to D.C. for grilling on campus antisemitismMay 22, 2024 | msn.comWhat's next for restaurants: Gene-edited salad greens, underground "delivery tubes"May 22, 2024 | yahoo.comGene Meyer found guilty of sexually assaulting, murdering Betty Rolf in 1988May 21, 2024 | msn.comGene Meyer convicted in 1988 murder of Betty RolfMay 21, 2024 | msn.comGene Meyer found guilty on murder & sexual assault charges from 1988 cold caseMay 21, 2024 | msn.comGene Pratter, federal judge overseeing Ozempic and Mounjaro lawsuits, dies at 75May 21, 2024 | usnews.com'Hungry Gut' Gene Test Shows Who'll Benefit Most From WegovyMay 20, 2024 | msn.comExploring the Gene Hackman Classic with a 100% Rating on Rotten TomatoesSee More Headlines Receive CRXM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Gene Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:CRXM Previous SymbolNYSE:CXM CUSIPN/A CIK772320 Webwww.cardiumthx.com Phone(858) 414-1477Fax858-436-1001Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta-0.14 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Christopher J. Reinhard (Age 70)Co-Founder, CEO, President, Treasurer & Director Comp: $240kMr. James L. Grainer (Age 69)Chairman, CFO & Secretary Dr. Lois A. Chandler (Age 66)Chief Operating Officer Dr. Ronald J. Shebuski (Age 71)Chief Scientific Officer Mr. Duane LinstromGeneral CounselKey CompetitorsAdvanced Life SciencesOTCMKTS:ADLSAVAX TechnologiesOTCMKTS:AVXTClarus TherapeuticsOTCMKTS:CRXTQCornwall ResourcesOTCMKTS:CORCEntera BioNASDAQ:ENTXView All Competitors CRXM Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Gene Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Gene Biotherapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Organovo (ONVO), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Adaptimmune Therapeutics (ADAP), Intellipharmaceutics International (IPCIF), MGT Capital Investments (MGTI) and Nokia Oyj (NOK). How do I buy shares of Gene Biotherapeutics? Shares of CRXM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CRXM) was last updated on 6/12/2024 by MarketBeat.com Staff From Our Partners$9 AI Model with 90% Win Rate?What if I told you it could take just $9… To win 90% of your options trades?Trade Machine | SponsoredThe Hidden Tax Advantages of America’s #1 Inheritance StockWall Street Millionaire: BUY "America's #1 Legacy Stock" The man CNBC called "The Prophet" bought AAPL at $...Stansberry Research | SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gene Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gene Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.